Moderna, Inc. (NASDAQ:MRNA) Stock Holdings Lowered by Legal & General Group Plc

Legal & General Group Plc cut its position in Moderna, Inc. (NASDAQ:MRNA) by 6.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,616,531 shares of the company’s stock after selling 186,341 shares during the quarter. Legal & General Group Plc owned about 0.68% of Moderna worth $310,713,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC bought a new stake in shares of Moderna during the second quarter valued at approximately $26,000. Cedar Wealth Management LLC increased its position in Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares during the period. Westside Investment Management Inc. acquired a new stake in Moderna in the 1st quarter valued at approximately $32,000. Family Firm Inc. acquired a new position in Moderna during the 2nd quarter worth $33,000. Finally, Rise Advisors LLC grew its stake in shares of Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after purchasing an additional 286 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on MRNA shares. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Friday, September 13th. Leerink Partners reduced their price target on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a research note on Tuesday, September 17th. Barclays lowered their price objective on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a research note on Monday, September 16th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and cut their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $75.00 price target on shares of Moderna in a research report on Thursday, September 19th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $100.44.

Insider Activity

In other news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, President Stephen Hoge sold 15,000 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00. Following the completion of the sale, the president now directly owns 1,442,089 shares of the company’s stock, valued at $174,665,819.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The disclosure for this sale can be found here. Insiders sold 78,158 shares of company stock worth $9,259,012 over the last quarter. Corporate insiders own 15.70% of the company’s stock.

Moderna Trading Up 2.8 %

Shares of MRNA opened at $65.75 on Friday. The business’s 50-day moving average price is $84.24 and its 200 day moving average price is $109.46. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $25.20 billion, a P/E ratio of -4.20 and a beta of 1.67. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same quarter in the previous year, the business earned ($3.62) earnings per share. The firm’s revenue was down 29.9% compared to the same quarter last year. Analysts expect that Moderna, Inc. will post -9.86 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.